Jasper Therapeutics - JSPR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $64.29
  • Forecasted Upside: 168.75%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$23.92
▲ +0.1 (0.42%)

This chart shows the closing price for JSPR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Jasper Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JSPR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JSPR

Analyst Price Target is $64.29
▲ +168.75% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Jasper Therapeutics in the last 3 months. The average price target is $64.29, with a high forecast of $80.00 and a low forecast of $40.00. The average price target represents a 168.75% upside from the last price of $23.92.

This chart shows the closing price for JSPR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Jasper Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$65.00Low
5/6/2024HC WainwrightInitiated CoverageBuy$65.00Low
4/3/2024Evercore ISIInitiated CoverageOutperform$65.00Low
3/28/2024Royal Bank of CanadaInitiated CoverageOutperform$70.00Low
3/18/2024TD CowenInitiated CoverageOutperformLow
3/7/2024OppenheimerReiterated RatingOutperform ➝ Outperform$80.00Low
11/8/2023William BlairReiterated RatingOutperformLow
10/12/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$60.00Low
8/14/2023Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$40.00Low
8/11/2023Capital One FinancialInitiated CoverageOverweight$70.00Low
5/15/2023Cantor FitzgeraldReiterated RatingOverweightLow
3/9/2023Credit Suisse GroupReiterated RatingOutperform$40.00Low
3/9/2023Cantor FitzgeraldReiterated RatingOverweight$60.00Low
3/9/2023EF Hutton Acquisition Co. IReiterated RatingBuy$68.50Low
2/27/2023EF Hutton Acquisition Co. IReiterated RatingBuy$68.50Low
2/17/2023EF Hutton Acquisition Co. IReiterated RatingBuy$40.00 ➝ $68.50Low
2/7/2023Cantor FitzgeraldLower TargetOverweight$100.00 ➝ $60.00Low
1/11/2023EF Hutton Acquisition Co. IReiterated RatingBuy$40.00Low
1/11/2023Credit Suisse GroupLower TargetOutperform$70.00 ➝ $30.00Low
11/16/2022Credit Suisse GroupLower Target$70.00Low
11/14/2022OppenheimerLower TargetOutperform$210.00 ➝ $80.00Low
11/1/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$40.00Low
7/13/2022Credit Suisse GroupLower TargetOutperform$90.00 ➝ $80.00Low
2/28/2022Cantor FitzgeraldInitiated CoverageOverweight$100.00Low
2/25/2022Credit Suisse GroupLower TargetOutperform$150.00 ➝ $100.00Medium
11/8/2021Credit Suisse GroupInitiated CoverageOutperform$150.00High
10/21/2021William BlairInitiated CoverageOutperformLow
10/20/2021BMO Capital MarketsInitiated CoverageOutperform$190.00Low
10/12/2021OppenheimerInitiated CoverageOutperform$210.00High
(Data available from 5/25/2019 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 6 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 8 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024

Current Sentiment

  • 8 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Jasper Therapeutics logo
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Read More

Today's Range

Now: $23.92
Low: $23.19
High: $24.33

50 Day Range

MA: $24.91
Low: $20.40
High: $30.00

52 Week Range

Now: $23.92
Low: $4.00
High: $31.01

Volume

143,905 shs

Average Volume

71,298 shs

Market Capitalization

$360.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Jasper Therapeutics?

The following Wall Street research analysts have issued research reports on Jasper Therapeutics in the last year: Cantor Fitzgerald, Capital One Financial Co., Credit Suisse Group AG, Evercore ISI, HC Wainwright, Oppenheimer Holdings Inc., Royal Bank of Canada, TD Cowen, and William Blair.
View the latest analyst ratings for JSPR.

What is the current price target for Jasper Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Jasper Therapeutics in the last year. Their average twelve-month price target is $64.29, suggesting a possible upside of 168.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting JSPR will reach $80.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $40.00 for Jasper Therapeutics in the next year.
View the latest price targets for JSPR.

What is the current consensus analyst rating for Jasper Therapeutics?

Jasper Therapeutics currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe JSPR will outperform the market and that investors should add to their positions of Jasper Therapeutics.
View the latest ratings for JSPR.

What other companies compete with Jasper Therapeutics?

How do I contact Jasper Therapeutics' investor relations team?

Jasper Therapeutics' physical mailing address is 1177 AVENUE OF THE AMERICAS FL 40, NEW YORK NY, 10036. The company's listed phone number is 650-549-1400 and its investor relations email address is [email protected]. The official website for Jasper Therapeutics is jaspertherapeutics.com. Learn More about contacing Jasper Therapeutics investor relations.